Skip to main content
. Author manuscript; available in PMC: 2021 Apr 1.
Published in final edited form as: Mol Cancer Ther. 2020 Aug 26;19(10):2034–2043. doi: 10.1158/1535-7163.MCT-19-1098

Fig. 3.

Fig. 3

Biodistribution of 177Lu-EB-RGD in PDX groups. (A) PDXαvβ3+ models at 4, 24, 48 and 72 h post-injection (n = 3). (B) Comparison of 177Lu-EB-RGD and 177Lu-RGD in PDXαvβ3+ models at 24 h post-injection (n = 3/group). (C) 177Lu-EB-RGD in PDXαvβ3- models at 4, 24, 48 and 72 h post-injection (n = 3/group). (D) Comparison of 177Lu-EB-RGD and 177Lu-RGD in PDXαvβ3- models at 24 h post-injection (n = 3/group).